<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0124-8146</journal-id>
<journal-title><![CDATA[Investigaciones Andina]]></journal-title>
<abbrev-journal-title><![CDATA[Investig. andina]]></abbrev-journal-title>
<issn>0124-8146</issn>
<publisher>
<publisher-name><![CDATA[Fundación Universitaria del Área Andina - FUNANDI]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0124-81462019000100153</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[FACTORES ASOCIADOS AL RETIRO TEMPRANO DEL JADELLE® EN UN PROGRAMA DE PLANIFICACIÓN FAMILIAR]]></article-title>
<article-title xml:lang="en"><![CDATA[FACTORS ASSOCIATED WITH THE EARLY REMOVAL OF JADELLE® IN A FAMILY PLANNING PROGRAM]]></article-title>
<article-title xml:lang="pt"><![CDATA[FATORES ASSOCIADOS À RETIRADA ANTECIPADA DO IMPLANTE JADELLE® EM UM PROGRAMA DE PLANEJAMENTO FAMILIAR]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuervo Patiño]]></surname>
<given-names><![CDATA[Clara Edith]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[Ludy Alexandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Niño Avendaño]]></surname>
<given-names><![CDATA[Carlos Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Pedagógica y Tecnológica de Colombia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Pedagógica y Tecnológica de Colombia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Pedagógica y Tecnológica de Colombia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>21</volume>
<numero>38</numero>
<fpage>153</fpage>
<lpage>166</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0124-81462019000100153&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0124-81462019000100153&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0124-81462019000100153&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: investigación que permitió determinar los factores asociados al retiro temprano de Jadelle® en las usuarias que asisten al programa de planificación familiar en la ESE Santiago de Tunja. La relevancia del estudio radica en la importancia de conocer los motivos y las causas de retiro que los profesionales de la salud deben informar a las usuarias para lograr una mayor comprensión y aceptación de las reacciones adversas, para así evitar el retiro temprano del implante.  Métodos: estudio descriptivo, cuantitativo, de corte transversal. La información se recolectó mediante la revisión de historias clínicas de 678 usuarias que se retiraron el Jadelle® entre julio de 2013 y junio de 2017.  Resultados: el porcentaje de retiro temprano del implante fue de 36,8%, con mayor número de retiro durante el periodo de uso entre 24 y 30 meses y entre 36 y 42 meses. La principal causa de retiro se asoció con la presencia de alguna reacción adversa por el uso del dispositivo, principalmente la hemorragia uterina disfuncional.  Conclusión: es frecuente el uso del Jadelle®, especialmente en mujeres jóvenes, y la tasa de continuidad de este dispositivo se puede aumentar si se detectan y se vigilan los factores asociados al retiro temprano, principalmente las reacciones adversas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: This research aimed to determine the factors associated with the early removal of Jadelle® in the users who are part of the family planning program at ESE Santiago of Tunja. This is a relevant study aim to identify the reasons and causes of removal which should be inform by health professionals to women in order to achieve a better understanding and acceptance of adverse effects, avoiding early removal of the implant.  Methods: Descriptive, quantitative, cross-sectional study. The information was collected by analyzing medical records of 678 subjects who removed the Jadelle® between July 2013 and June 2017.  Results: The percentage of the implant early removal was 36.8%, there was a greater amount of removals during the period between 24 and 30 months and 36 and 42 months of use. The main cause of removal was associated with the presence of an adverse reaction produce by the device, mainly dysfunctional uterine bleeding.  Conclusion: The use of Jadelle® is common, especially in young women. The continuity rate of this device can be increased if the factors associated with early removal are detected and monitored, especially adverse reactions.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução. Investigação que permitiu determinar os fatores associados à retirada antecipada do implante Jadelle® nos usuários que frequentam o programa de planejamento familiar na ESE Santiago de Tunja. Estudo importante para conhecer os motivos e as causas de retirada que os profissionais de saúde devem informar aos usuários para melhor compreensão e aceitação das reações adversas, evitando a retirada antecipada do implante.  Métodos. Estudo descritivo, quantitativo, transversal. As informações foram coletadas através da revisão de registros médicos de 678 usuários que retiraram o Jadelle® entre julho de 2013 e junho de 2017.  Resultados. A percentagem de retirada antecipada do implante foi de 36,8%, com maior número de retiradas no período entre 24 e 30 meses e 36 e 42 meses de uso. A principal causa de retirada foi associada à presença de uma reação adversa devido ao uso do dispositivo, principalmente hemorragia uterina disfuncional.  Conclusão. O uso do implante Jadelle® é frequente, principalmente em mulheres jovens; a taxa de continuidade deste dispositivo pode ser aumentada se os fatores associados à retirada antecipada forem detectados e monitorados, especialmente as reações adversas.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Levonogestrel]]></kwd>
<kwd lng="es"><![CDATA[efectos colaterales]]></kwd>
<kwd lng="es"><![CDATA[reacciones adversas relacionados con medicamentos]]></kwd>
<kwd lng="es"><![CDATA[anticonceptivos]]></kwd>
<kwd lng="en"><![CDATA[Levonogestrel]]></kwd>
<kwd lng="en"><![CDATA[Side Effects and Adverse Reactions related to drug contraceptives]]></kwd>
<kwd lng="pt"><![CDATA[Levonogestrel]]></kwd>
<kwd lng="pt"><![CDATA[efeitos colaterais e reações adversas relacionadas a medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[contraceptivos]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montenegro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lara]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Velásquez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implantes anticonceptivos]]></article-title>
<source><![CDATA[Perinatol Reprod Hum]]></source>
<year>2005</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-43</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Profamilia Colombia</collab>
<source><![CDATA[Informe Anual de Actividades]]></source>
<year>2015</year>
<publisher-name><![CDATA[Profamilia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<source><![CDATA[Diccionario de especialidades farmacéuticas, PLM® Colombia]]></source>
<year>2012</year>
<edition>40</edition>
<page-range>1219</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuleta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Anticonceptivos de reciente introducción en el Mercado]]></source>
<year>2005</year>
<volume>XIII</volume>
<page-range>12-23</page-range><publisher-name><![CDATA[Memorias Curso de Actualización en Obstetricia y Ginecología]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patiño]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución a un año de los efectos adversos, en una cohorte de pacientes con implante subdérmico de desogestrel]]></article-title>
<source><![CDATA[Rev chil obstet ginecol]]></source>
<year>2006</year>
<volume>71</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>170-3</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roche]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Whitehead]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New Zealand women's experience during their first year of Jadelle contraceptive implant]]></article-title>
<source><![CDATA[Journal of primary health care]]></source>
<year>2016</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sivin]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk and benefits, advantages and disadvantages of Levonorgestrelreleasing contraceptive implants]]></article-title>
<source><![CDATA[Drug Safety]]></source>
<year>2003</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>303-35</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of the subdermal contraceptive etonogestrel implant (Implanon®) on biochemical and hormonal parameters (three years follow-up)]]></article-title>
<source><![CDATA[Eur J Contracept Reprod Health Care]]></source>
<year>2008</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>238-42</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hincapié]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Causas de abandono, cambio o fallo terapéutico de la anticoncepción hormonal en mujeres universitarias]]></article-title>
<source><![CDATA[Revista CES]]></source>
<year>2013</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>153-62</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Profamilia</collab>
<source><![CDATA[Encuesta Nacional de Demografía y Salud (ENDS)]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-Acting Reversible Contraception]]></article-title>
<source><![CDATA[Rev Bras Ginecol Obstet]]></source>
<year>2017</year>
<volume>39</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>294-308</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calixto]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ospina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Manrique]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retiro temprano del implante subdérmico con etonogestrel en usuarias de un programa de anticoncepción de Tunja - Boyacá, Colombia]]></article-title>
<source><![CDATA[Universidad y salud]]></source>
<year>2015</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>224-32</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<collab>Consejo Nacional de Seguridad Social en Salud</collab>
<source><![CDATA[Acuerdo Número 380. Por medio del cual se incluyen medicamentos anticonceptivos hormonales y el condón masculino en el Plan Obligatorio de Salud del Régimen Contributivo y del Régimen Subsidiado]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Bogotá, D.C. ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de la Protección Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balogun]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Afolabi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Adeniran]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Saidu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Jadelle® sub-dermal implant: evaluation of acceptance, effectiveness, side effects and discontinuation in Ilorin, Nigeria]]></article-title>
<source><![CDATA[East and Central Africa Medical Journal]]></source>
<year>2014</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>69-73</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berenson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hirth]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complications and continuation rates associated with 2 types of long-acting contraception]]></article-title>
<source><![CDATA[American Journal of Obstetrics &amp; Gynecology]]></source>
<year>2015</year>
<volume>761</volume>
<page-range>e1-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlates and consequences of early removal of levonorgestrel implants among teenaged mothers]]></article-title>
<source><![CDATA[Arch Pediatr Adolesc Med]]></source>
<year>1998</year>
<volume>152</volume>
<page-range>893-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Maya]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Osorio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Posada]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad y efectos adversos de los implantes anticonceptivos Norplant]]></article-title>
<source><![CDATA[CES Medicina]]></source>
<year>1997</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-15</page-range><publisher-loc><![CDATA[Antioquia ]]></publisher-loc>
<publisher-name><![CDATA[Clínica de Especialistas CES de Sabaneta]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características demográficas y los efectos adversos del Jadelle® comparado con el implanón en usuarias del servicio de salud reproductiva en INPPARES]]></article-title>
<source><![CDATA[Revista salud, sexualidad y sociedad]]></source>
<year>2008</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>10-4</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Angarita]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Composición, mecanismo de acción y efectos adversos de los implantes subdérmico usados como método anticonceptivo: una revisión de literatura]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de ciencias aplicadas y ambientales ciencias de la salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuenca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Causas de abandono del implante subdérmico utilizado como método anticonceptivo por las pacientes atendidas en el hospital universitario de Motupe, en el período de mayo-agosto 2014]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Loja ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional de Loja]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blumenthal]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gemzell]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Marintche-va]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tolerability and clinical safety of Implanon]]></article-title>
<source><![CDATA[Eur J Contracept Reprod Health Care]]></source>
<year>2008</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-36</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glasier]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implantable contraceptives for women: effectiveness, discontinuation ratios, return of fertility and outcome of pregnancies]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>2002</year>
<volume>65</volume>
<page-range>29-30</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sivin I Lahteenmaki]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ranta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levonorgestrel concentrations during use of levonorgestrel rod [LNG ROD] implants]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>1997</year>
<volume>55</volume>
<page-range>81</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
